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Abstract. A side effect of diabetes is formation of gly-
cated proteins and, from them, production of ad-
vanced early glycation end products that could de-
termine aberrant immune responses at the systemic 
level. We investigated a relevant aberrant post-trans-
lational modification (PTM) in diabetes based on 
synthetic peptides modified on the lysine side chain 
residues with 1-deoxyfructopyranosyl moiety as a 
possible modification related to glycation. The PTM 
peptides were used as molecular probes for detection 
of possible specific autoantibodies developed by dia-
betic patients. The PDC-E2(167-186) sequence from 
the pyruvate dehydrogenase complex was selected 
and tested as a candidate peptide for antibody detec-
tion. The structure-based designed type I’ β-turn 
CSF114 peptide was also used as a synthetic scaffold. 
Twenty-seven consecutive type 1 diabetic patients 
and 29 healthy controls were recruited for the study. 
In principle, the ‘chemical reverse approach’, based 
on the use of patient sera to screen the synthetic 
modified peptides, leads to the identification of spe-
cific probes able to characterize highly specific au-
toantibodies as disease biomarkers of autoimmune 
disorders. Quite surprisingly, both peptides modified 
with the (1-deoxyfructosyl)-lysine did not lead to sig-
nificant results. Both IgG and IgM differences be-
tween the two populations were not significant. These 
data can be rationalized considering that i) IgGs in 
diabetic subjects exhibit a high degree of glycation, 
leading to decreased functionality; ii) IgGs in diabet-
ic subjects exhibit a privileged response vs proteins 
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containing advanced glycation products (e.g., meth-
ylglyoxal, glyoxal, glucosone, hydroimidazolone, di-
hydroxyimidazolidine) and only a minor one with re-
spect to (1-deoxyfructosyl)-lysine.
Introduction 
Chemical modifications of proteins have to be con-
sidered as an important aspect in the pathogenesis of a 
series of diseases, among which diabetes is the most rel-
evant one. In these pathological conditions, an increase 
of yield of the reaction between glucose and protein 
amino functions (e.g., N-terminal function, lysine, and 
arginine side-chains), following the pathway originally 
described by Maillard (1992), is observed. After the 
sugar is added to the protein, a Schiff base is formed, 
which in turn rearranges itself, leading to the so-called 
Amadori product (fructosamine). It is important to em-
phasize that all the species present in the reaction path-
way (sugar, Schiff base, fructosamine) are to be consid-
ered responsible as the starting point for production of a 
wide number of α-oxoaldehydes called advanced glyca-
tion end products (AGEs). 
Recently, Ahmed and Thornalley (2007) discussed 
the relevance of AGEs in diabetic complications and 
they compared the traditional view and new insights 
into the protein glycation in diabetes, showing that a dif-
ferent panorama has now to be considered (see Table 1). 
In general, the predominant early glycation adduct is Nϵ-
fructosyl-lysine (FL), which degrades slowly to form 
many different AGEs (Thornalley, 2005), mainly dicar-
bonyls (RDCs), glyoxal (G), methylglyoxal (MG), and 
3-deoxyglucosone (3DG), which are potent glycation 
agents (as an example, MG is 20,000 more reactive than 
glucose!). MG primarily reacts with arginine residues to 
form neutral ring structures: dihydroxyimidazolidine 
(MG-DH) and hydroimidazolone (MG-HI). These as-
pects must be necessarily considered in studies related 
to the monitoring of glycation processes.
Matrix-assisted laser desorption/ionization (MALDI) 
mass spectrometry (Lapolla et al., 2006) was proved to 
be a valid analytical tool to evaluate the glycation level 
of circulating proteins. In fact, considering that each glu-
cose molecule linked to a protein leads to a mass in-
crease of 162 Da, the mass difference (ΔM) between the 
mass values of glycated and unglycated proteins divided 
by 162 (the molecular mass, in Dalton, of dehydrated 
glucose) gives directly an evaluation of the number of 
glucose molecules condensed on the protein (Lapolla 
et al., 2011). Considering the above-reported view of 
Ahmed and Thornalley (2007), this number is to be con-
sidered a lower limit: in fact, dehydration and oxidation 
processes present in the Maillard reaction pattern lead to 
species linked to the protein of lower mass. Furthermore, 
the same protein can be modified not by reaction with 
glucose, but also by its above-described reaction with 
GO and MGO on arginine. The effectiveness of the 
MALDI approach in the study of proteins modified in 
vivo by reaction with sugars and AGEs was proved by a 
series of investigations based on the comparison of cir-
culating proteins in healthy subjects and diabetic patients, 
proving that, as an example, human serum albumin 
(HSA) is widely glycated in diabetic patients (Lapolla et 
al., 2011), as shown by a clear mass increase in the case 
of diabetic patients. This aspect is certainly relevant 
considering that HSA is the most abundant transport 
protein and that glycation can somehow inhibit the bind-
ing sites responsible for the transport of biologically rel-
evant molecules. But is this the only relevant behaviour? 
Alternatively to the MALDI approach, a further view 
can be considered from both biochemical and biological 
aspects: the development of an aberrant immune re-
sponse against the modified proteins originated from the 
above-described glycation processes could be activated 
at the systemic level. Then, a study based on the use of 
synthetic peptides specifically modified on the lysine 
side chain residues with different biologically relevant 
aberrant post-translational modifications (PTMs) was 
undertaken to investigate these aspects. 
The aberrant PTM peptides were used as molecular 
probes for detection of possible specific autoantibodies 
developed by diabetic patients and, to a lower extent, by 
control subjects.
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Table 1. The relevance of AGEs in diabetic complications
Traditional view of glycation
Glucose-driven reaction forms Amadori products.
Advanced glycation end products (AGEs) are formed slowly in post-Amadori pathways under physiological conditions.
Chemically stable AGEs accumulate on extracellular proteins.
Chemically stable AGEs on long-lived proteins accumulate progressively throughout lifespan.
AGEs are lysine residue-derived adducts.
New insights of physiological glycation
AGEs are formed from α-oxoaldehydes produced by the degradation of glycolytic intermediates, lipid peroxidation and Schiff base 
fragmentation.
α-Oxoaldehydes are arginine-directed glycating agents, forming hydroimidazolones – quantitatively important AGEs with 
relatively short half-lives (12–60 days).
Cellular proteins are modified significantly by AGEs – particularly renal glomeruli, retina, and peripheral nerve in diabetes.
AGE-modified proteins are degraded by cellular proteolysis to AGE free adducts and excreted in the urine. They accumulate 
markedly in diabetes and in uraemia. AGEs are lysine residue-derived adducts.
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Due to our interest in diabetes, from both medical and 
analytical point of view (Szymanski and Wren, 2005; 
Lapolla et al., 2013), we initially focused our attention 
on glycation. Because of the demonstrated role of mito-
chondrial machinery in diabetes, the sequence and 
chemical modification of the E2 component of pyruvate 
dehydrogenase complex PDC-E2 was considered as an 
interesting candidate antigen (Van de Water et al., 1988). 
In fact, this protein plays a key role in the energy me-
tabolism of cells. In particular, PDC-E2 is involved in 
the oxidative decarboxylation of pyruvates linking the 
glycolysis metabolic pathway to the citric acid cycle. 
This aspect was proved during the characterization of 
the immunodominant epitope of anti-mitochondrial an-
tibodies in a different autoimmune disease, primary bil-
iary cirrhosis, leading to the discovery of the highly con-
served domain surrounding a lipoyl-lysine residue in 
position 173 (K173) within the hPDC-E2(167-186) frag-
ment (Reche and Perham, 1999). In fact, the amino acid 
linear peptide A167EIETDK173ATIGFEVQEEGYL186 is 
the epitope of the 74-kD mitochondrial autoantigen of 
primary biliary cirrhosis and corresponds to the func-
tional site of dihydrolipoamide acetyltransferase (Wallis 
and Perham, 1994). Therefore, K173 in the PDC-E2 
(167–186) peptide sequence was considered to be an in-
teresting site to investigate for possible aberrant chemi-
cal modifications triggering an immune response in dia-
betes (Fig. 1A).
Consequently, the PDC-E2(167-186) sequence was 
selected and tested as a candidate peptide for antibody 
detection because of its strong involvement at the mito-
chondrial level in the energy cycle of cells and glucose 
metabolism. On the other hand, the structure-based de-
signed type I’ β-turn peptide sequence CSF114 was also 
used as a synthetic scaffold (Lolli et al., 2005b). Its op-
timized β-turn conformation was previously developed 
to maximize the exposure of different PTMs to the ex-
ternal media, in order to assess the hypothetical specific-
ity of the peptide sequence and/or of the chemical mod-
ifications introduced towards serum autoantibodies 
(Carotenuto et al., 2006, 2008; Nuti et al. 2010). There-
fore, the type I’ β-turn peptide CSF114 sequence was 
the one selected to assess the role of the specific PDC-E2 
(167–186) sequence or of the secondary structure in Ag-
Ab recognition in diabetes (Fig. 1B). 
Specifically, we decided to investigate the 1-deoxy-
fructosyl moiety (deoxyFru) as a possible aberrant PTM 
related to glycation (Fig. 1). DeoxyFru is an intermedi-
ate of the Maillard reaction pattern, responsible for pro-
duction of a high number of α-oxoaldehydes (dicarbo-
nyls (RDCs), glyoxal (G), methylglyoxal (MG), and 
3-deoxyglucosone (3DG); however, it degrades slowly 
(Thornalley, 2005) and consequently could be in princi-
ple considered a valid target. The selected peptides were 
tested in a cohort of type 1 diabetic patient (TD1) sera 
and non-diabetic subject sera as controls (NBD) to as-
sess their usefulness as molecular probes for the detec-
tion of Abs in the sera of different subjects. 
Material and Methods
Subjects
Twenty-seven (27) consecutive type 1 diabetic pa-
tients (TD1), regularly attending the Diabetology and 
Dietetics outpatients Clinic of Padova University, and 
29 healthy controls (NBD) were recruited for the study. 
TD1 subjects were treated with insulin (four injections/
day). In the morning, after a 12 h overnight fast, blood 
samples were taken to determine fasting plasma glucose 
(FPG), HbA1c, and autoantibody levels. After collection, 
blood was immediately centrifuged at 1,700 g and +4 °C 
for 20 min. Glucose was measured immediately and the 
rest of the sample was frozen to –80 °C until analysis.
The study protocol complied with the Helsinki De-
claration and written informed consent was obtained 
from all subjects before their participation in the study.
MW-assisted solid phase peptide synthesis
All Fmoc-protected amino acids, Fmoc-Wang resins, 
DIC (N,N′-diisopropylcarbodiimide), and Oxyma were 
purchased from Iris Biotech GmbH (Marktredwitz, 
Fig. 1. (A) NMR structure of the apo form of PDC-E2 (pdb 
code 1FYC, orange ribbon) (Pacini et al., 2015). Only Lys173 
side chain is reported for clarity. Strand numbering of the 
original work is reported as S1-S8. Structures are shown 
with the same spatial orientation. (B) Hypothetical in-solu-
tion structure of the synthetic deoxyfructosylated type I’ 
β-turn peptide CSF114 (Lolli et al., (2005b).
*K173: lysine: modification site with the deoxyfructosyl 
moiety R; *K7: lysine modification site with the deoxy-
fructosyl moiety R.
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Germany). Fmoc-Lys(Boc) (2,3:4,5-di-O-isopropylide-
ne-1-deoxyfructopyranosyl)-OH was prepared as previ-
ously described (Carganico et al., 2009).
[(DeoxyFru)Lys173]PDC-E2(167-186)-KKKK (1), 
[(deoxyFru)Lys7]CSF114 (2) were synthesized by micro-
wave-assisted solid-phase peptide synthesis (MW-SPPS) 
following the Fmoc/tBu strategy, using the Liberty 
BlueTM automated microwave peptide synthesizer (CEM 
Corporation, Matthews, NC) (Nuti et al., 2010). The resin 
used was Fmoc-Lys(Boc)-Wang (loading 0.31 mmol/g). 
Fmoc-Lys(Boc)(2,3:4,5-di-O-isopropylidene-1-deoxy-
fructopyranosyl)-OH (2.5 equiv.) was coupled for 40 min 
at room temperature (r.t.) using HATU (2.5 equiv.) and 
NMM (3.5 equiv.) in DMF. Micro-cleavages, to monitor 
couplings, were performed with a microwave apparatus 
CEM DiscoverTM single-mode MW reactor (CEM Cor-
poration). Final cleavage was performed using a mix-
ture of TFA/TIS/H2O (95 : 2.5 : 2.5 v : v : v) for 6 h at r.t.
Purification of the synthetic peptides was performed 
by semi-preparative RP-HPLC in a Waters instrument 
(Separation Module 2695, detector diode array 2996) 
using a Phenomenex (Torrance, CA) Jupiter column 
C18 (10 μm, 250 × 10 mm) at 4 ml/min with solvent 
systems A (0.1% TFA in H2O) and B (0.1% TFA in 
CH3CN). Characterization of the peptides was per-
formed by analytical UPLC, using a Waters ACQUITY 
UPLC (Waters Corporation, Milford, MA) coupled to a 
single quadrupole ESI-MS (Waters 3100 Mass Detector) 
using a BEH C18 (1.7 μm, 2.1 × 50 mm) column at 
35 °C, at 0.6 ml/min with solvent systems A (0.1% TFA 
in H2O) and B (0.1% TFA in CH3CN). The peptides 
were purified by semi-preparative RP-HPLC and char-
acterized by RP-HPLC ESI-MS, obtaining a final purity 
≥ 98 % (Table 2). 
Immunoassays
Immunoassays, to detect IgM or IgG in the sera, were 
performed by solid-phase Enzyme-Linked Immuno-
Sorbent Assays (SP-ELISA), coating the synthetic pep-
tides on 96-well plates Nunc Maxisorp® (Sigma-Aldrich, 
Milano, Italy). Washing steps were executed with an 
automatic Hydroflex microplate washer (Tecan Italia, 
Milano, Italy). Anti-human IgG-alkaline phosphatase 
con jugates were purchased from Sigma-Aldrich and 
anti-human IgM-alkaline phosphatase were purchased 
from Invitrogen (Life Technologies, Monza, Italy). p-Ni-
trophenyl phosphate was purchased from Sigma-Aldrich. 
Absorbance values were measured in a Sunrise Tecan 
ELISA plate reader purchased from Tecan. 
Activated polystyrene 96-well ELISA plates were 
coated with 100 μl/well of 1 : 100 diluted synthetic pep-
tides, independently, in 0.05 M pure carbonate buffer 
(pH 9.6). After overnight incubation at 4 °C, plates were 
washed three times using washing buffer (0.9% NaCl 
and 0.05% Tween 20 in Milli-Q water). Nonspecific 
binding sites were blocked with 100 μl/well of foetal 
bovine serum (FBS) buffer (10% FBS in washing buff-
er) at r. t. for 1 h. FBS buffer was removed and plates 
were incubated overnight with the sera (100 μl/well, di-
luted 1 : 100 in FBS buffer) at +4 °C. After three wash-
es, plates were treated with 100 μl/well of anti-human 
IgG or anti-human IgM alkaline phosphatase-conjugat-
ed antibody diluted in FBS buffer (1 : 8,000 for anti-
human IgG, 1 : 1,200 for anti-human IgM). After 3 h of 
incubation at r. t. and three washes, 100 μl of substrate 
buffer (pNPP 1 mg/ml in alkaline substrate buffer pH 
9.8, consisting of 10% diethanolamine and 0.1% MgCl2 
in Milli-Q water) was added to each well. After 15–30 
min incubation at r. t., the absorbance of each plate 
was read in a multichannel ELISA reader at 405 nm (ref 
620 nm). ELISA plates, coating conditions, reagent di-
lutions, buffers, and incubation times were tested in pre-
liminary experiments. All buffers were brought to room 
temperature prior to use and filtered through 0.22 μm 
filters (except FBS buffer). The antibody levels are ex-
pressed as absorbance in arbitrary units at 405 nm.
Basic blood chemistry parameters
HbA1c was measured by high-performance liquid 
chromatography (HPLC, Menarini Akray ADAM A1c 
HA-8180 v), in line with IFCC standards (International 
Federation of Clinical Chemistry) (Mosca et al., 2013). 
Plasma glucose was measured with a glucose-oxidase 
method (McMillin, 1990).
Statistical analysis 
Data are expressed as mean ± SD. Student’s t-test for 
unpaired data was used to compare continuous variables 
between the groups. Least-square linear regression anal-
ysis was used to test any relationship between pairs of 
variables. Differences were deemed statistically signifi-
cant when P < 0.05 (two-tailored test).
Table 2. Analytical data of the synthetic peptides
N° Synthetic peptides Semi-prep HPLC 
gradient
UPLC/HPLC 
(Rt, min)
ESI-MS [M+3H]3+ (m/z) found 
(calculated)
1 [(deoxyFru)Lys173]PDC-E2(167-186)-KKKK 20–35% B in 30 min 1.80a,b 973.6 (2918.3)
2 [(deoxyFru)Lys7]CSF114 25–40% B in 30 min 3.99a,c 874.8 (2620.4)
a UPLC performed in Acquity system with 3100 mass detector (Waters); column: BEH C
18
 1.7 μm, 2.1 × 50 mm (Waters); eluents: A: 
0.1% TFA in H2O, B: 0.1% TFA in CH3CN; flow: 0,6 ml/min.
b Gradient 10–50% B for 3 min. c Gradient 20–70% B for 3 min.
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The mean values (± SD) of IgG were very low (TD1-1: 
0.02 ± 0.02; TD1-2: 0.03 ± 0.06 AU; (NBD-1: 0.04 ± 
0.02; NBD-2: 0.08 ± 0.12 AU). IgM values were slight-
ly higher than the IgG values in both TD1 (TD1-1: 0.21 
± 0.11; TD1-2: 0.22 ± 0.14 AU) and NBD subjects 
(NBD-1: 0.19 ± 0.11; NBD-2: 0.17 ± 0.1 AU), further 
evidencing no meaningful differences between the two 
groups, thus allowing us to assume that the 1-deoxy-
fructosyl moiety (deoxyFru) as a possible aberrant PTM 
is irrelevant.
No relationships were found between autoantibody 
levels (either IgG and IgM), fasting plasma glucose, 
HbA1c, and duration of the disease in the patients evalu-
ated.
Discussion
It has been widely reported that hyperglycaemia can 
lead to the formation of advanced glycation end prod-
ucts (AGEs), which are part of the normal metabolism, 
but when expressed in excess (as in the case of hyper-
glycaemia), become pathological for tissues, altering 
the cellular structure and function and promoting oxida-
tive stress (Brownlee et al. 1984; Ulrich and Cerami, 
2001). Therefore, it appears relevant to investigate the 
PTMs of proteins possibly present in hyperglycaemia. It 
has been reported in the literature that humans and ani-
mals generate antibodies to modified forms of LDL, ei-
ther oxidized or glycated (Lopes-Virella et al., 1997, 
2007). Both IgG and IgM antibodies have been detected 
in humans. IgG isolated from the sera of diabetic pa-
tients and healthy controls reacts with oxidized human 
LDL in vitro, forming immune complexes (Virella et al., 
2008). 
In the case of AGE-modified LDL, the main modifi-
cation recognized by these antibodies was carboxyme-
thyl lysine. As described in the introduction, glycation 
Results
The clinical and metabolic characteristics of the pa-
tients under study are reported in Table 3 showing that 
diabetic patients have significantly higher values of fast-
ing plasma glucose and HbA1c with respect to the con-
trols.
Sera from 27 TD1 and 29 NBD subjects were tested 
by SP-ELISA using the synthetic peptides 1 and 2. The 
applied ELISA protocol for detection of IgM and IgG 
antibodies against [(deoxyFru)Lys173]PDC-E2(167-186)- 
KKKK and [(deoxyFru)Lys7]CSF114 antigens was pre-
viously developed and applied routinely in our labora-
tory for [Lys173]PDC-E2(167-186)-KKKK and [Lys7]
CSF114 antigens (Lolli et al 2005a; Pacini et al. 2015; 
Nuti et al. 2018). The obtained IgM and IgG data distri-
bution is reported in Fig. 2. 
The chemical-physical properties of the peptide anti-
gen do not change by modifying Lys in position 17 of 
the CSF114 sequence or in position 173 of PDC-E2(167-
186)-KKKK.
The synthetic peptides 1 and 2 failed to detect specific 
antibodies against non-enzymatic glycation products. 
Table 3. Clinical characteristics of the subjects under study
Type 1 diabetes NBD
Number 27 29
Age (years) 42.0 ± 10.0 41.0 ± 3.0†
Disease duration (years) 10.0 ± 8.0 – 
BMI 25.0 ± 0.8 24.0 ± 1.5†
Fasting plasma glucose 
(mg/dl)
136.0 ± 30.0 83.5 ± 4.8*
HbA1c (%) 7.3 ± 1.8 5.2 ± 0.2*
* P < 0.05 1 vs 2; † P = 0.05 1 vs 2
Fig. 2. Total IgG (A) and total IgM (B) titres in 27 TD1 and 29 NBD subjects, detected by SP-ELISA using the synthetic 
deoxyfructosylated antigens: [(deoxyFru)Lys173]PDC-E2(167-186)-KKKK (1) and [(deoxyFru)Lys7]CSF114 (2).
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of proteins occurs through spontaneous and reversible 
condensation of a reducing sugar on a free amino group 
of a protein, to form a Schiff base. This then undergoes 
rearrangement into a more stable ketoamine, also known 
as the Amadori product. In the case of glucose, the ini-
tially formed Schiff base rearranges into the more stable 
1-deoxyfructosyl moiety (see lower part of Fig. 1). 
Subsequent dehydration, fragmentation, oxidation, and 
cyclization reactions lead to the irreversible formation 
and release of AGEs (Brownlee et al. 1984; Ulrich and 
Cerami, 2001). Different methods have been utilized 
until now to estimate the amount of glycation products, 
e.g., spectroscopic methods (Maillard, 1912; Lapolla et 
al., 2005), showing however severe limitations in the 
evaluation of the general level of glycation and unable 
to identify the structure of the glycated protein. Recently, 
more accurate methods have been employed, such as 
liquid chromatography (LC), radioimmunoassay (RIA), 
and mass spectrometry (MALDI, ESI/MS, LC/MS) 
(Brownlee et al. 1984; Lapolla et al. 2005, 2006, 2011, 
2013, Szymanski and Wren, 2005; Vlassara, and Uribarri, 
2014). In this context, methods able to evaluate specific 
antibodies against non-enzymatic glycation products 
represent a challenge, especially when these antibodies 
exhibit high specificity. 
We previously proposed to use peptides as synthetic 
antigens for efficient detection, including the afore-
mentioned chemical modifications in the strategic posi-
tions in selected sequences. In particular, we employed 
CSF114 as an optimally designed β-turn conformation, 
and the PDC-E2(167-186) fragment, which is a mito-
chondrial protein component of the pyruvate dehydro-
genase complex (Lolli et al 2005b; Pacini et al. 2015; 
Nuti et al. 2018).
The relevant part of the antigen derived from the na-
tive protein sequence and reproducing specific epitopes, 
or mimicking immunogenic modifications, has been 
synthetically reproduced. This approach can be even 
more effective and specific than using the native pro-
teins to detect antibodies. In fact, its principal advantage 
is the complete control of the synthetic molecules, either 
of the sequence or of the insertion of the correct aberrant 
PTM at a suitable position. The folding issue can also be 
partly reproduced: in fact, synthetic peptides, through 
sequence optimization, can adopt specific conforma-
tions, e.g., β-turns. This approach could have some lim-
its due to the choice of the aberrant PTM peptides that 
surely can exhibit only one structural change and that, 
anyway, unlikely reproduce the 3D structure and distri-
bution of the charged peptides around the modified ly-
sine groups in the actual protein. As an example, this 
view is supported by literature data (Virella et al., 2005) 
proving that there is very little cross-reactivity of iso-
lated human antibodies to AGE-LDL with CML-
modified human serum albumin. However, following 
this view, we synthesized peptides 1 and 2 (Table 2) that 
were tested by SP-ELISA of type-1 diabetes sera and 
NBD sera as controls to assess their usefulness as mo-
lecular probes for detection of antibodies. We are con-
scious that in the case of glycation processes, the anti-
bodies would be developed not only vs fructosyl-lysine, 
but also vs modified proteins originating by the reac-
tions with GO and MGO described above, leading to HI 
and DHI species.
It has been previously successfully demonstrated that 
synthetic peptides exposing an aberrant PTM are valid 
tools to detect antibodies in autoimmune diseases, like 
in primary biliary cirrhosis and multiple sclerosis (Lolli 
et al., 2005a,b; Pacini et al., 2015; Walvoort et al., 2016; 
Nuti et al., 2018). These tools can be generated by the 
so-called ‘chemical reverse approach’ (CRA), based on 
the use of patient sera to screen focused libraries of syn-
thetic modified peptides. These peptides can allow ef-
fective identification of specific probes for the charac-
terization of autoimmune disorders. Considering that 
the antibodies can be directed to the protein domain ex-
posing a PTM residue through a key-lock interaction, 
the CRA would be focused on: (a) identification of the 
side-chain modification involved in the pathogenetic 
mechanism of a specific autoimmune disease, by screen-
ing peptide libraries based on PTM diversity; (b) struc-
ture-activity relationship studies for the selection of the 
best peptide sequence by screening peptide libraries.
In the present investigation, the CSF114 β-turn struc-
ture was tested as a synthetic scaffold for its intrinsic 
characteristic of best exposing the (1-deoxyfructosyl)-
lysine moiety as an aberrant modification. 
Quite surprisingly, as shown by the data reported in 
Fig. 2, the relatively low titres observed for both anti-
gens 1 and 2 indicate neither specificity nor any mean-
ingful difference in antibody response (either IgM or 
IgG titre) between the patients and controls.
Then, at first sight, this result seems to indicate com-
plete ineffectiveness of the CRA method in characteriz-
ing the immune response in diabetes. It must be stressed 
that this view is just addressed to the protein glycation 
phenomenon, and a different explanation can be given 
to rationalize these data. First of all, our results can be 
compared with those obtained in previous studies of an-
tibody reactive AGEs (Turk et al., 2001) and to carboxy-
methyl lysine (CML), considered an enzymatic diges-
tion product of glycated proteins (Vay et al., 2000). In 
the latter case, differences between patient and control 
sera were found. However, anti-CML IgGs in diabetic 
patient sera were unrelated to the disease duration and 
metabolic control (Vay et al., 2000). Moreover, lower 
anti-AGE antibody titres were observed in the diabetic 
patients vs controls. This unexpected result was justified 
by Turk et al. (2001) with formation of an in vivo im-
mune complex exhibiting the effective key-lock interac-
tion between the antibodies and antigen. In principle, 
these results give us an answer to the lack of reactivity 
observed in our case. However, alternatively to the 
Turk’s proposal, a possible explanation can be related to 
structural changes of the antibodies more than of the an-
tigen.
IgGs in diabetic subjects exhibit a high degree of gly-
cation similarly as other circulating proteins, necessarily 
F. Nuti et al.
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leading to decreased functionality (Lapolla et al., 1997, 
2000). The significant increase in IgG glycation levels 
has been studied (Lapolla et al., 1997, 2000). When ap-
plied to three different populations (healthy subjects, 
well controlled, and poorly controlled diabetic patients), 
MALDI mass spectrometry found mean ΔM values of 
581 Da for healthy subjects, 1,128 Da for well con-
trolled, and 2,556 Da for poorly controlled diabetic pa-
tients, corresponding respectively to at least 4, 7, and 16 
glucose molecules condensed on the protein. Although 
MALDI MS can determine the mean total number of 
glucoses condensed on IgGs, this technology cannot 
provide information related to the changes in activity of 
the Fab and Fc portions. To investigate this aspect, in 
vitro experiments were carried out, proving that the Fab 
moiety is the most prone to glycation. In fact, enzymatic 
digestion and MALDI analysis of the digestion products 
proved the presence of 20 glucose molecules condensed 
on the Fab portion and 10 on the Fc moiety. These find-
ings were also confirmed by computer molecular mod-
elling. The solvent-accessible surfaces were calculated 
for each lysine residue, confirming that these are more 
exposed in the Fab moiety, and that consequently Fab 
fragments are more prone to the glucose attack, particu-
larly in their light and heavy variable regions (VL and 
CL). These structural moieties are highly important in 
the process of molecular recognition in the key-lock in-
teraction between antibody and antigen. It is reasonable 
to assume that the same behaviour is displayed by IgMs.
The above-described extensive glycation of immuno-
globulins in the presence of high glucose levels neces-
sarily leads to the molecular architecture different from 
the unglycated one, and consequently exhibiting differ-
ent reactivity. This can be the rationale of the new data 
described here pertaining to the use of CRA in diabetes 
monitoring. The lack of antibody recognition by gly-
cated peptides can be due to the ineffectiveness of gly-
cated antibodies present during the diabetic disease.
A further explanation of the negative results obtained 
by CRA in the present study is that, differently to what 
is observed in primary biliary cirrhosis, in in vivo sam-
ples from diabetic subjects the DeoxyFru moiety could 
be a minor component due to its degradation leading to 
AGEs. In other words, it must be considered that IgGs 
in diabetic subjects could exhibit a privileged response 
vs proteins containing advanced glycation products 
(methylglyoxal, glyoxal, glucosone, hydroimidazolone, 
dihydroxyimidazolidine) and only a minor one with re-
spect to (1-deoxyfructosyl)-lysine. Works are now in 
progress for the synthesis of HI- and DHI-containing 
model peptides to verify the validity of this hypothesis.
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